

CS (Lux) Global Biotech Innovators Equity Fund

Investment policy

This sector-based equity fund globally invests in stocks of biotechnology companies to achieve long-term capital appreciation while maintaining an adequate distribution of risks. It offers access to one of the fastest-growing segments of the health sector, and opportunity to participate in growth in value tied to clinical progress of innovative products from early stage to those ready to be brought to market. The fund invests in numerous therapeutics areas, as well as diagnosis and preventative treatments. The portfolio is not constrained either in terms of geography or by market capitalization. The NASDAQ Biotechnology TR serves as the benchmark.

Fund facts

Fund manager	
Credit Suisse AM Then	natic Equity Team
Fund manager since	15.12.2016
Location	Zurich
Fund domicile	Luxembourg
Fund currency	USE
Close of financial year	30. Sep
Total net assets (in millions)	148.48
Inception date of share class	23.09.2014
Management fee in % p.a.	0.90
TER (as of 30.09.2016) in %	1.24
Benchmark (BM)	No Benchmark
Swinging single pricing (SSP) ³⁾	Yes

Unit Class Category IBH (capital growth)

(capital growth)
EUR
LU0491223573
CSBIBHE LX
1'240.02
500'000
Daily

Austria, Chile, France, Germany, Italy, Liechtenstein, Luxembourg, Singapore, Spain, Switzerland 3) For more details, please refer to the relevant chapter "Net

Asset Value" of the Fund's prospectus.

Fund Statistics

	1 year	3 years
Annualized volatility in %	16.33	25.14
Tracking Error (Ex post)	-	-
Beta	-	-





Net performance in EUR²⁾

	1 month	3 months	YTD	1 year	3 years	5 years
Fund	1.61	-3.27	26.26	21.33	10.73	-
Fund	1.61	-3.27	26.26	21.33	10.73	


Sectors in %

	Fund
Biotechnology	72.11
Life Sciences Tools & Services	8.44
Health Care Equipment	8.13
Pharmaceuticals	7.27
Health Care Services	3.09
Cash/Cash Equivalents	0.96

Sales

70

Currencies in %




Significant Transactions	
Purchases	

Number of holdings	

Fund

Countries in %



Top 10 holdings in %

Biogen	3.26
Amgen	3.14
Biomarin Pharmaceutical	3.07
Gilead Sciences	3.03
Incyte	3.00
Teladoc	3.00
Celgene	2.99
Illumina	2.95
Vertex Pharma	2.92
Alnylam Pharmaceuticals	2.72
Total	30.08

1) The calculation of the risk indicator is based on the CESR/10-673 Directive. The risk indicator is based on historic and partly simulated data; it cannot be used to predict future developments. The classification of the Fund may change in future and does not represent a guarantee. A classification into category 1 is not a risk-free investment either.

2) Historical performance indications and financial market scenarios are not reliable indicators of future performance. The performance data do not take into account the commissions and costs incurred on the issue and redemption of fund units. 1/2

The disclaimer mentioned at the end of this document also applies to this page

Contact

CREDIT SUISSE AG Sucursal en España Calle Ayala 42 28001 Madrid/Spain Tel +34 91 791 60 00 Fax +34 91 791 60 10

This document has been prepared by Credit Suisse AG and/or one of its affiliates (hereafter "CS") with the greatest of care and to the best of its knowledge and belief. However, CS provides no guarantee with regard to its content and completeness, and does not accept any liability for losse which might arise from making use of this information. The opinions expressed in this document are those of CS at the the recipient. It does not constitute an offer or recommendation to buy or sell financial instruments or banking services and does not release the recipient from exercising his/her own judgment. In particular, the recipient is advised to check that the information provided is in line with his/her own circumstances with regard to any legal, regulatory, tax or other consequence, with the help of a professional advisor if necessary. This document may not be reproduced in part or in full without the written permission of CS. Neither this document nor any copy thereof may be sent, taken into or distributed in the United States or to any US person (within the meaning of Regulation S of the US Securities Act of 1993) in its current form). It is not intended for persons who, due to their nationality or place of residence, are not permitted access to such information under local law. Every investment involves risk, especially with regard to fluctuations in value and return. Investments in foreign currency might lose value against the investor's reference currency. Neither historical nor future performance indicators and financial market scenarios are guarantee for current or future performance. Performance cando the transactions in the products or services mentioned herein, Credit Suisse AG may pay to or receive from third parties one-time or recurring remunerations as part of its compensation. You may request further information from your financial advisor. Potential conflicts of interest cannot be excluded. This document qualifies as marketing material that has been published for advertising purposes. It should not

Copyright © 2017 Credit Suisse Group AG and/or its affiliates. All rights reserved.